Medtronic Study Finds High Use of App-Based Remote Cardiac Monitoring Among Older Patients
May 17 2017 - 9:00AM
Nearly 90 Percent
of Patients 71 and Older Met Clinical Guidelines for Remote
Monitoring
DUBLIN and CHICAGO- May 17, 2017
- A new Medtronic plc (NYSE: MDT) study shows a high use of
app-based remote cardiac monitoring among older patients. Presented
at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual
Scientific Sessions, the first-of-its-kind study evaluated 15,595
patients across 1,969 clinics with Medtronic pacemakers who were
assigned a MyCareLink Smart(TM) app-based remote monitor.
The study found that 88.4 percent of patients of
all ages who were prescribed this new technology used their smart
devices to successfully activate their MyCareLink Smart mobile app,
and 89.7 percent remained "adherent" by transmitting data to the
Medtronic CareLink(TM) Network within 12 months, the minimum
frequency recommended by the HRS and European Heart Rhythm
Association expert consensus.
Age was not a clinically significant factor in
activating or adhering the app-based monitoring at 12 months, with
89.4 percent of patients aged 71 and older using the app to
transmit data, compared to 86.7 percent of patients 18-50 and 91
percent for those 51-70.
"There is often a misperception that older
patients aren't adapting to newer technologies, but this study
shows that is not the case," Khaldoun Tarakji, M.D., M.P.H.,
electrophysiologist and director of clinical electrophysiology
research at the Cleveland Clinic, who led the study. "Hundreds of
thousands of pacemakers are implanted every year in the United
States, and the majority of them in patients over 65 years of age.
Physicians should discuss the importance of remote monitoring with
patients, regardless of their age." Dr. Tarakji has received
compensation from Medtronic as an invited speaker and educator and
is a scientific advisory board member.
Approved by the U.S. Food and Drug Administration
(FDA) in November 2015, the MyCareLink Smart patient monitor is the
world's first app-based remote monitoring system for patients with
implantable cardiac devices. With the MyCareLink Smart monitor,
patients can use their own smartphone or tablet technology, with
cellular or Wi-Fi service, to securely transmit data from their
cardiac device to their physicians, who can then interpret the data
to make treatment decisions.
By connecting patients and physicians, remote
cardiac monitoring provides many clinical and economic benefits.
These include faster time to treatment if the physician detects a
problem with the pacemaker based on the transmitted
data;1 less
time spent at a doctor's office or clinic for regular checks of the
pacemaker;2,3 reduced
time spent in the hospital if the physician quickly detects and
treats a medical problem;1,4 and a
potential increase in patient survival rates.4,5,6
"The MyCareLink Smart Monitor was designed to
provide seamless compatibility with devices that patients use every
day," said Aisha Barry, vice president and general manager for the
Connectivity & Insights business, which is part of the Cardiac
and Vascular Group at Medtronic. "We are encouraged this study
shows such a high rate of patient use of remote monitoring with our
app-based offering, particularly among our older pacemaker
patients."
In collaboration with leading clinicians,
researchers and scientists worldwide, Medtronic offers the broadest
range of innovative medical technology for the interventional and
surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company strives to offer products and services of
the highest quality that deliver clinical and economic value to
healthcare consumers and providers around the world.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 88,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
1 Crossley
GH, et al. J Am Coll
Cardiol. 2011;57:1181-1189.
2 Cronin
EM, et al. Heart
Rhythm. 2012;9:1947-1951.
3 Varma N,
et al. Am Heart
J. 2007;154:1029-1034.
4 Akar J,
et al. LB03-03 Presented at HRS 2014.
5 Saxon
LA, et al. Circulation. 2010;122:2359-2367.
6 Mittal
S, et al. LB01-05 Presented at HRS 2014.
Contacts:
Ryan Mathre
Public Relations
+1-763-514-9625
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024